Screener
Relmada Therapeutics, Inc. RLMD Deferred Tax Assets and Other Non-Current Assets
Deferred Tax Assets and Other Non-Current Assets at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.
The source filing: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001213900-26-055059
| Line item | As of / March 31, | As of |
|---|---|---|
| Short-term investments | 224,186,743 | 89,509,710 |
| Prepaid expenses | 1,380,151 | 977,721 |
| Total current assets | 235,343,294 | 93,983,971 |
| Other assets | 19,500 | 19,500 |
| Total assets | $235,362,794 | $94,003,471 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $5,731,401 | $1,568,944 |
Item 1. Unaudited Condensed Consolidated Financial Statements
FAQ
- What is Relmada Therapeutics, Inc.'s deferred tax assets and other non-current assets?
- Relmada Therapeutics, Inc. (RLMD) reported deferred tax assets and other non-current assets of $19.5K in Q1 2026.
- How has Relmada Therapeutics, Inc.'s deferred tax assets and other non-current assets changed year-over-year?
- Relmada Therapeutics, Inc.'s deferred tax assets and other non-current assets decreased by 11.3% year-over-year, from $21.98K to $19.5K.
- What is the long-term trend for Relmada Therapeutics, Inc.'s deferred tax assets and other non-current assets?
- Over 5 years (2020 to 2025), Relmada Therapeutics, Inc.'s deferred tax assets and other non-current assets has grown at a -23.1% compound annual growth rate (CAGR), from $41K to $11K.
Ask your AI about Relmada Therapeutics, Inc.'s deferred tax assets and other non-current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude